340B Program May Be Reducing Biosimilar Uptake
New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.
Stay updated with breaking news from Drug Pricing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.
The title of CMS’s May 26 proposed rule, “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the MDRP,” buries the lede. Amid twenty Medicaid Drug...
The 340B Drug Pricing Program allows community health centers and about 50 qualified hospitals in Arkansas to buy discounted prescription drugs from manufacturers, using the money to improve patient care.
On May 23, 2023, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule entitled Misclassification of Drugs, Program Administration and Program Integrity Updates...
For 340B, a program granting cheaper medicines to nonprofit healthcare patients, drug industry innumeracy is only rivaled by its greed.